Details 13 Related Guidelines / Approvals

Indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.

type

FDA Approval

approval date

2022-03-11

settings
settings
Adjuvant
settings
Early stage
settings
High risk
source

FDA